- Home
- SNGX vs EVAX Comparison
SNGX vs EVAX Comparison
Compare SNGX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- EVAX
- Stock Information
- Founded
- SNGX 1987
- EVAX 2008
- Country
- SNGX United States
- EVAX Denmark
- Employees
- SNGX N/A
- EVAX N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNGX Health Care
- EVAX Health Care
- Exchange
- SNGX Nasdaq
- EVAX Nasdaq
- Market Cap
- SNGX 10.1M
- EVAX 17.8M
- IPO Year
- SNGX 1987
- EVAX 2021
- Fundamental
- Price
- SNGX $2.79
- EVAX $2.94
- Analyst Decision
- SNGX Strong Buy
- EVAX Strong Buy
- Analyst Count
- SNGX 1
- EVAX 2
- Target Price
- SNGX $6.00
- EVAX $10.00
- AVG Volume (30 Days)
- SNGX 871.1K
- EVAX 71.6K
- Earning Date
- SNGX 11-07-2025
- EVAX 10-30-2025
- Dividend Yield
- SNGX N/A
- EVAX N/A
- EPS Growth
- SNGX N/A
- EVAX N/A
- EPS
- SNGX N/A
- EVAX N/A
- Revenue
- SNGX N/A
- EVAX $3,176,000.00
- Revenue This Year
- SNGX N/A
- EVAX N/A
- Revenue Next Year
- SNGX N/A
- EVAX $425.50
- P/E Ratio
- SNGX N/A
- EVAX N/A
- Revenue Growth
- SNGX N/A
- EVAX 1042.45
- 52 Week Low
- SNGX $1.09
- EVAX $1.20
- 52 Week High
- SNGX $6.23
- EVAX $17.20
- Technical
- Relative Strength Index (RSI)
- SNGX 49.04
- EVAX 52.53
- Support Level
- SNGX $2.58
- EVAX $2.81
- Resistance Level
- SNGX $2.98
- EVAX $3.04
- Average True Range (ATR)
- SNGX 0.20
- EVAX 0.20
- MACD
- SNGX -0.08
- EVAX -0.01
- Stochastic Oscillator
- SNGX 32.81
- EVAX 71.19
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.